Sartorius, a Goettingen, Germany-based international pharmaceutical and laboratory tools provider, acquired ViroCyt Inc., a Broomfield, Colorado, USA-based innovator in the field of rapid virus quantification.
Led by Robert Kline, President and CEO, ViroCyt provides virus-related research and product development solutions to pharma and biopharma R&D laboratories, vaccine manufacturers as well as from academic institutes focused on virology. The company is expected to generate more than $3 million sales revenues in 2016 while achieving break even underlying EBITDA by the end of 2018.
The transaction valued ViroCyt at approx. $16m.
Founded in 1870, the Sartorius Group is an international pharmaceutical and laboratory equipment provider with two divisions:
– Bioprocess Solutions, which offers single-use solutions to allow customers to produce biotech medications and vaccines;
– Lab Products & Services, which offers laboratory instruments, consumables and services.
The company earned sales revenue of more than 1.1 billion euros in 2015.
FinSMEs
17/07/2016